UK – NICE publishes updated guidance with expanded recommendation for Oncotype DX

The National Institute for Health and Care Excellence (NICE) has announced the release of a second set of guidelines recommending three tests as options to help NHS clinicians decide whether to prescribe chemotherapy for some people with early breast cancer.

NICE’s previously published guidelines from 2013 recommended Oncotype DX Breast Recurrence Score to help determine which patients need chemotherapy.

The Institute acknowledges Oncotype DX as the only test that reduces the overall number of patients who receive chemotherapy, as well as the only test supported by long-term patient outcomes evidence.

The updated guidelines have, however, recommend two further tests: Myriad Genetics’ EndoPredict, and NanoString Technologies’ Prosigna as alternative options…